

## RESEARCH OPPORTUNITY

NAMI is committed to improving the lives of people impacted by mental health conditions through effective treatments, equitable public policies, and greater knowledge and understanding in society. Research is essential to advance each of these goals. When NAMI is approached to be involved in research of any type, at any level, we take it very seriously. NAMI's Chief Medical Officer Dr. Ken Duckworth and Chief Program Officer Dr. Teri Brister thoroughly review the research protocols and methodology and the documentation that the study has been approved by an Institutional Review Board (IRB) to assure the safety of those involved.

NAMI does not accept financial compensation for recruiting research participants. NAMI also does not endorse any products or treatments. We share these research opportunity notices with you, our field leaders, to distribute at your discretion if you believe that members of your community may be interested in participating in these studies.

If you have questions about research at NAMI, please visit [NAMI.org/research](https://www.nami.org/research) or email [research@nami.org](mailto:research@nami.org).

## WHAT IS THE STUDY?

Risk evaluation and mitigation strategy (REMS) programs are a federally mandated part of taking certain medications and can include various types of patient monitoring, prescribing restrictions, and physician and pharmacy training and certification. This study is designed to better understand individual experiences with REMS programs as a requirement of taking the medication clozapine (Clozaril) via remote, phone-based qualitative interviews. The goal of this study is to learn about the impact of current REMS programs on patient populations in order to improve these programs in the future. Total participation time is about 60 minutes. Participants who complete the interview will receive a \$50 Amazon gift card.

## WHO CAN PARTICIPATE?

Individuals may be eligible for this study if they:

- Are 18 years of age or older
- Are taking or have taken clozapine (Clozaril) or care for someone who is taking or has taken clozapine (Clozaril)

*Note: Non-English speakers will not be prevented from participation provided they have an interpreter with them.*

There will be 160 people total participating in this study - 20 people will be recruited for their experience with clozapine REMS, while the remaining participants will be recruited for experience with different REMS programs.

## WHERE IS THE STUDY TAKING PLACE?

This study will be taking place remotely, via phone.

## HOW DO I LEARN MORE?

The documents attached have additional information about the study. If you have questions or would like more information, please contact Dr. Ameet Sarpatwari at [asarpatwari@bwh.harvard.edu](mailto:asarpatwari@bwh.harvard.edu).